Cancer
Malignant Colon Neoplasm
CI-CAN-00007995Explore in graph →
Top-level225 active trials5 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007995Explore in graph →
Clinical trials
1,196 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (139)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05513742 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer(COMPANION-003) | completed | Phase 2 | 49 | Compass TherapeuticsINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 |
| clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06714292 | Fluorescent Approach for Refined Endoscopic Marking With Clip Localization and Identification Procedure(FLARECLIP) | completed | Phase 2 | 110 | Seoul National University HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT00159484 | Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 75 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03446157 | Palbociclib and Cetuximab in Metastatic Colorectal Cancer | completed | Phase 2 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT00826540 | Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 83 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05510895 | Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer(NeoBRAF) | completed | Phase 2 | 2 | AIO-Studien-gGmbHOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT02978612 | Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III(ACE) | completed | Phase 2 | 170 | Oslo University HospitalOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT03482362 | Vinorelbine in Advanced BRAF-like Colon Cancer(EORTC1616) | completed | Phase 2 | 1 | The Netherlands Cancer InstituteOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03442569 | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | completed | Phase 2 | 56 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT02368886 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 123 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04625803 | Neoadjuvant Therapy for Locally Advanced Colon Cancer | completed | Phase 2 | 64 | Zhejiang UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT04554836 | MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | completed | Phase 2 | 6 | TheraOpOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06804876 | COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients | completed | Phase 2 | 107 | Zhejiang UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT02138617 | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | completed | Phase 2 | 100 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT00200200 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer | completed | Phase 2 | 73 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02861300 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | David Bajor, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05662527 | Response to Immunotherapy in MMR-deficient Localized Colon Cancer(RESET-C) | completed | Phase 2 | 85 | Camilla QvortrupOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT00788957 | Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | completed | Phase 1 / Phase 2 | 177 | NantBioScience, Inc.INDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06454071 | Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients | completed | Phase 2 | 75 | Soonchunhyang University HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT02834052 | Pembrolizumab + Poly-ICLC in MRP Colon Cancer | completed | Phase 1 / Phase 2 | 42 | Asha NayakOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT00407654 | VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05468892 | Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial(VELO) | completed | Phase 2 | 68 | University of Campania Luigi VanvitelliOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT00019760 | Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03428126 | Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT03332498 | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | completed | Phase 1 / Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT03359681 | Metformin Treatment for Colon Cancer(MECORA) | completed | Phase 2 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT00193219 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01902953 | Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) | completed | Phase 2 | 16 | Maimonides Medical CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials